Key Market Indicator:
Welcome our new Research Provider
In the Research & Ratings section, you can access assessments from renowned analyst firms that specialize in the due diligence and valuation of companies that are generally listed on the stock exchange. Starting from the research reports, you can access further research tools and information with just a few mouse clicks, which offer you additional options for obtaining and assessing information.
DE000A0HGQF5
Wed, 27.07.2022
MagForce AG
MagForce AG unexpectedly files for insolvency; price target and rating
suspended
In an announcement dated 26.07.2022, MagForce AG informed the capital
market, to our complete surprise, that it intends to file for insolvency
proceedings due to insolvency. According to the company's announcement,
this had become necessary after reorganisation meas [ … ]
Wed, 27.07.2022
MagForce AG
MagForce AG unexpectedly files for insolvency; price target and rating
suspended
In an announcement dated 26.07.2022, MagForce AG informed the capital
market, to our complete surprise, that it intends to file for insolvency
proceedings due to insolvency. According to the company's announcement,
this had become necessary after reorganisation meas [ … ]
Wed, 13.07.2022
MagForce AG
- Stage 2b of the trial for approval in the USA is currently ongoing
- Billing code by the American Medical Association is available
- Break-even expected from 2024
In the past financial year 2021, MagForce AG continued or resumed the
planned European roll-out for the treatment of malignant brain tumours
(glioblastoma). The four NanoActivator de [ … ]
Wed, 13.07.2022
MagForce AG
- Stage 2b of the trial for approval in the USA is currently ongoing
- Billing code by the American Medical Association is available
- Break-even expected from 2024
In the past financial year 2021, MagForce AG continued or resumed the
planned European roll-out for the treatment of malignant brain tumours
(glioblastoma). The four NanoActivator de [ … ]
Wed, 09.02.2022
MagForce AG
In the past fiscal year 2021, MagForce AG made progress in both business
segments. Of particular note here is the approval granted by the FDA for
the start of Stage 2b for the treatment of prostate cancer patients. This
means that the pivotal study could be concluded as early as summer 2022. In
parallel, the treatment capacities for the indication [ … ]
Mon, 15.11.2021
MagForce AG
1st HY 2021: FDA approval for final pivotal study received, forecasts and
price target confirmed, rating: BUY
In the context of the research study (Anno) of 20.07.2021, we had already
postulated our expectations that MagForce AG would probably report low
treatment figures overall in Europe (indication area: glioblastoma) in the
first half of 202 [ … ]
Mon, 18.10.2021
MagForce AG
FDA announces conditions for the final pivotal study; study
expected to start in 2021 and to be completed in mid-2022; timeframe
largely in line with our expectations; forecasts, price target and BUY
rating confirmed
According to corporate news of 13.10.2021, MagForce AG has made significant
progress in obtaining approval for the treatment of pr [ … ]
Tue, 20.07.2021
MagForce AG
- Approval for prostate treatment imminent,
- New treatment devices to be installed in Europe,
- Strong growth and break-even expected from 2022 onwards
Despite pandemic-related restrictions, MagForce AG made further progress in
2020 in the commercialisation of its own technology. For the alreadyapproved
treatment of malignant brain tumours in [ … ]
Thu, 29.04.2021
MagForce AG
Further results of the pivotal study 2a confirm expectations, market
approval in 2021 still in prospect, price target of EUR 11.00 and BUY
rating confirmed
After MagForce AG announced the successful completion of stage 2a of the
pivotal study for the treatment of prostate cancer in the USA in February
2021, the company has published additional, [ … ]
Fri, 18.12.2020
MagForce AG
Capital increase of EUR4.7m successfully implemented to finance growth
strategy, high share price potential, BUY rating confirmed
Since our last research study (see research study dated 12.11.2020), the
share price of MagForce AG has developed significantly positively. Within
just one month, the share price has risen significantly by approximate [ … ]